Jan 04, 2022 8:00am EST Ensysce Biosciences Achieves Successful Completion of Part A of Multiple-Ascending Dose (MAD)/Bioequivalents (BE) Trial for its Next Generation Opioid, PF614
Dec 15, 2021 4:05pm EST Ensysce Biosciences Announces First Patients Enrolled in Phase 1 Study of PF614-MPAR™, its unique technology platform to provide opioid overdose protection
Nov 30, 2021 8:00am EST Ensysce Biosciences Announces Clinical Trial Progress of its New Class of Opioids
Nov 15, 2021 5:32pm EST Ensysce Biosciences Reports Third Quarter 2021 Financial Results and Recent Corporate Updates
Nov 08, 2021 8:00am EST Ensysce Biosciences Announces Completion of $15 Million Convertible Note Financing
Oct 26, 2021 8:00am EDT Ensysce Biosciences Grows its Management Team with Appointment of Dr. Linda Pestano as Chief Development Officer
Sep 08, 2021 8:00am EDT Ensysce Biosciences Announces Treatment of First Cohort for Subjects in Clinical Study of its Next Generation Opioid, PF614
Aug 19, 2021 8:00am EDT Ensysce Biosciences to Host Satellite Symposium with Dr. Jeffrey Gudin at PAINWeek 2021 on September 9, 2021
Aug 16, 2021 4:45pm EDT Ensysce Biosciences Reports Second Quarter 2021 Financial Results and Recent Corporate Updates